Clinical Trial Update: Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating lenvatinib for patients with non-resectable hepatocellular carcinoma on the liver transplant waiting list after TACE failure…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Hepatocellular Carcinoma Non-resectable | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING